相关实验视频
Updated: Sep 10, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
在2型糖尿病中每周服用一次的胰岛素icodec与每日服用胰岛素glargine:一项具有纵向洞察力的元分析
Taimoor Ashraf1, Akshy Kumar2, Aniket Tara2
1Department of Medicine, Nishtar Medical University, Multan, Pakistan.
Annals of medicine and surgery (2012)
|August 25, 2025
概括
每周服用一次的胰岛素icodec可有效控制2型糖尿病 (T2DM) 的血糖水平,相当于每天服用的胰岛素glargine. 这种减少的注射频率可能会改善患者的治疗坚持和满意度.
科学领域:
- 内分泌学
- 代谢疾病
- 药理学
背景情况:
- 2型糖尿病 (T2DM) 的治疗通常需要胰岛素治疗.
- 坚持每日注射胰岛素可能是患者面临的重大挑战.
- 减少注射频率可能会改善治疗顺应性和长期结果.
研究的目的:
- 评估每周一次的胰岛素icodec与每天一次的胰岛素glargine U100的疗效和安全性.
- 评估减少注射频率对T2DM血糖控制的影响.
主要方法:
- 根据柯克兰和PRISMA指南进行系统审查和元分析.
- 包括随机对照试验 (RCT),比较T2DM成年人每周一次的胰岛素icodec与每天一次的胰岛素glargine U100.
- 使用随机效应模型进行数据合成.
主要成果:
- 对2019名参与者的5个RCT进行了分析.
- 与胰岛素glargine相比,胰岛素icodec显著降低了糖化血红蛋白 (HbA1c) 和增加了时间范围 (TIR).
- 包括低血糖和不良反应在内的安全性概况相似;在使用胰岛素iCodec时,体重略有增加.
结论:
- 每周服用一次的胰岛素是治疗T2DM的安全有效替代方案.
- 它提供与日常胰岛素glargine可比的血糖控制,剂量不太频繁.
- 减少注射负担有可能提高患者的坚持和满意度.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
257
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
257
Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Insulin Formulations: Types and Delivery
270
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
270
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K

